NewLink and Roche Pair Off on Cancer Immunotherapy
Insights - NewLink (NLNK) and Roche (RHHBY) will collaborate on the development of new IDO inhibitors, and combinations with NLNK's NLG919.
Read nowSearch Results for gene therapy
Takeaways from OncoGeneX’s Second Quarter Results
Research - Takeaways from OncoGeneX's (OGXI). Knowing this could make or save you some $$.
PremiumNo One’s Excited about OncoGeneX, Which Makes it Worth a Look
Research - OGXI is a speculative, micro-cap oncology company – now, essentially a call option with multiple shots on goal. $60 million in cash/equivalents provide a backdrop … Continue Reading
Premium
Sanofi and Regeneron’s RA Drug Plays in an Increasingly Crowded Market
Insights - Sarilumab, a new Rheumatoid Arthritis (RA) drug from Sanofi (SNY) and Regeneron (REGN), showed positive results in its first Phase 3 clinical trial. If approved, … Continue Reading
Read nowRegeneron: Q2 Results & Eylea Data Support the Long-Term Thesis
Long Ideas - Regeneron Pharmaceuticals (REGN), due in large part to the continued growth of Eylea, has become the world’s 5th largest biotechnology company by market capitalization. Regeneron, … Continue Reading
Read nowOnyx Coexisting with Celgene, Expanding Market – And Revenues Show It
Long Ideas - Since our original report on Onyx Pharmaceuticals (ONXX) in March, shares of the oncology drug developer have risen 14.8%, versus a 13.05% rise for the … Continue Reading
Read nowThe Beginning of a Shift at Tekmira: From Focus on Delivery, to Therapy
Long Ideas - Tekmira’s (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the … Continue Reading
Read now